SEOUL, July 26 (AJP) - Amorepacific's dermatological skincare brand Aestura announced Friday it will launch in Canada and Australia in August, expanding its global presence following its February entry into the U.S. market. The Korean beauty company will distribute products through Sephora stores in both countries as part of its exclusive partnership with the global cosmetics retailer.
The brand will focus on its Atobarrier 365 product line in the new markets, launching eight products including the flagship Atobarrier 365 cream, bubble cleanser, serum, hydro essence, lotion, soothing cream, mist and body lotion. The company will also offer a bestseller trial kit alongside the main product range. The Atobarrier 365 cream has sold over 7 million units since its launch.
Aestura first entered international markets in September 2023 with Japan, followed by Vietnam, Thailand and the United States. The brand initially gained traction in the U.S. through Amazon before officially launching through Sephora in February 2025. The company said the products performed well on Amazon rankings prior to the official Sephora launch.
In an interview with this publication, an Amorepacific representative said the company does not disclose brand-specific sales figures when asked about expected revenue from the Canadian and Australian markets. The representative noted that Aestura products had gained popularity through cross-border purchases on Amazon before the official U.S. launch, with the Atobarrier cream receiving particularly positive reception.
"Aestura as a brand has heritage from Taepyeongyang Pharmaceutical. Based on Amore research, we will continue to approach with the mindset of always thinking about customers with sensitive skin," the company representative told this publication. The brand plans to continue expanding into additional global markets following the Canada and Australia launches, targeting consumers seeking dermatological skincare solutions.
reporter
Candice Kim
candicekim1121@ajupress.com
Copyright ⓒ Aju Press All rights reserved.
View more comments